No Data
No Data
Taking A Look At Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) ROE
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson
Hainan Huluwa Pharmaceutical Group (605199.SH): Received notice of compliance inspection for pharmaceutical GMP.
On June 4th, Gelonhui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) has recently received a "Drug GMP Compliance Inspection Notice" issued by the Hainan Provincial Drug Administration. This GMP compliance inspection passed for the first time in the production workshops and production lines of the newly built Meanwell Intelligent Manufacturing Base of the company, indicating that the production workshops and production lines related to the production base meet the requirements of drug GMP, which will help the company continue to maintain stable product quality and production capacity to meet market demand.
Huluwa (605199.SH): Received a government subsidy of 16.209 million yuan
Gelonghui, May 30丨Huluwa (605199.SH) announced that from May 28, 2024 to the date of this announcement, the company and its subsidiaries received a total of RMB 16,209,443.35 (unaudited) of government subsidies related to revenue, accounting for 15.22% of the company's net profit attributable to owners of the parent company in 2023.
Hulu Wa (605199.SH): Received a government subsidy of 14.2998 million yuan
Gelonghui, May 27丨Huluwa (605199.SH) announced that from January 1, 2024 to the date of this announcement, the company and its subsidiaries received a total of RMB 14,299,792.79 (unaudited) of government subsidies relating to revenue, accounting for 13.43% of the company's net profit attributable to owners of the parent company in 2023.
Gourd Wa (605199.SH): No synthetic biological products or technical reserves
Gelonghui, May 14, 丨 Huluwa (605199.SH) said on the investor interactive platform that the company obtained the “Drug Registration Certificate” for terbutaline sulfate atomized inhalation solution approved and issued by the State Drug Administration on April 23, 2024, and has not yet been sold. There are currently no synthetic biological products or technology reserves.
Huluwa Pharmaceutical Gets Nod to Register Two Drugs
Hainan Huluwa Pharmaceutical Group (SHA:605199) obtained a drug registration certificate from China's National Medical Products Administration for bromhexine hydrochloride injection and desloratadine
No Data